[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07619443":3,"trial-entities:NCT07619443":145,"trial-summary:NCT07619443":148},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":41,"secondary_outcomes":56,"sex":102,"minimum_age":103,"maximum_age":104,"healthy_volunteers":105,"eligibility_criteria":106,"std_ages":114,"locations":116,"central_contacts":131,"overall_officials":136,"references":140,"see_also_links":141},"NCT07619443","7262-003","A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)","A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants","RECRUITING","2026-09-12","2026-07","2026-07-13","2026-07-01","Merck Sharp & Dohme LLC","INDUSTRY",false,"The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.",null,[19],"Healthy",[],"INTERVENTIONAL","BASIC_SCIENCE",[24],"PHASE1",{"count":26,"type":27},30,"ESTIMATED",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33},"DRUG","MK-7262","Oral administration",[31,34],"MK-7262 plus Enlicitide",{"type":30,"name":36,"description":32,"armGroupLabels":37,"otherNames":38},"Enlicitide",[36,34],[39,40],"enlicitide decanoate","MK-0616",[42,46,50,53],{"measure":43,"description":44,"timeFrame":45},"Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262","Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.","Predose and at designated time points post-dose (up to 8 days)",{"measure":47,"description":48,"timeFrame":49},"AUC0-inf of Enlicitide","Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.","Predose and at designated time points post-dose (up to 8 days post-dose)",{"measure":51,"description":52,"timeFrame":49},"Maximum Plasma Concentration (Cmax) of MK-7262","Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.",{"measure":54,"description":55,"timeFrame":49},"Cmax of Enlicitide","Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.",[57,61,64,67,70,73,76,79,82,85,88,91,94,98],{"measure":58,"description":59,"timeFrame":60},"Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262","Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.","Predose and at designated time points post-dose (up to 24 hours post-dose)",{"measure":62,"description":63,"timeFrame":49},"Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262","Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.",{"measure":65,"description":66,"timeFrame":49},"Time to Maximum Plasma Concentration (Tmax) of MK-7262","Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.",{"measure":68,"description":69,"timeFrame":49},"Apparent Terminal Half-life (t1\u002F2) of MK-7262","Blood samples will be collected at multiple time points to estimate the t1\u002F2 of MK-7262.",{"measure":71,"description":72,"timeFrame":49},"Apparent Clearance (CL\u002FF) of MK-7262","Blood samples will be collected at multiple time points to estimate the CL\u002FF of MK-7262.",{"measure":74,"description":75,"timeFrame":49},"Apparent Volume of Distribution During Terminal Phase (Vz\u002FF)of MK-7262","Blood samples will be collected at multiple time points to estimate the Vz\u002FF of MK-7262.",{"measure":77,"description":78,"timeFrame":60},"AUC0-24 of Enlicitide","Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.",{"measure":80,"description":81,"timeFrame":49},"AUC0-last of Enlicitide","Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.",{"measure":83,"description":84,"timeFrame":49},"Tmax of Enlicitide","Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.",{"measure":86,"description":87,"timeFrame":49},"t1\u002F2 of Enlicitide","Blood samples will be collected at multiple time points to estimate the t1\u002F2 of enlicitide.",{"measure":89,"description":90,"timeFrame":49},"CL\u002FF of Enlicitide","Blood samples will be collected at multiple time points to estimate the CL\u002FF of enlicitide.",{"measure":92,"description":93,"timeFrame":49},"Vz\u002FF of Enlicitide","Blood samples will be collected at multiple time points to estimate the Vz\u002FF of enlicitide.",{"measure":95,"description":96,"timeFrame":97},"Number of Participants Who Experience One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.","Up to approximately 8 weeks",{"measure":99,"description":100,"timeFrame":101},"Number of Participants Who Discontinue Study Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.","Up to approximately 6 weeks","ALL","19 Years","55 Years",true,{"inclusion":107,"exclusion":110,"raw_text":113},[108,109],"Is in good health before randomization","Has a body mass index (BMI) ≥18 and ≤32 kg\u002Fm\\^2, inclusive",[111,112],"Has a history or presence of clinically significant medical or psychiatric condition or disease","Has a history of cancer","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health before randomization\n* Has a body mass index (BMI) ≥18 and ≤32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history or presence of clinically significant medical or psychiatric condition or disease\n* Has a history of cancer",[115],"ADULT",[117],{"facility":118,"status":8,"city":119,"state":120,"zip":121,"country":122,"contacts":123,"geoPoint":128},"Celerion ( Site 0001)","Lincoln","Nebraska","68502","United States",[124],{"name":125,"role":126,"phone":127},"Study Coordinator","CONTACT","402-476-2811",{"lat":129,"lon":130},40.8,-96.66696,[132],{"name":133,"role":126,"phone":134,"email":135},"Toll Free Number","1-888-577-8839","Trialsites@msd.com",[137],{"name":138,"affiliation":13,"role":139},"Medical Director","STUDY_DIRECTOR",[],[142],{"label":143,"url":144},"Merck Clinical Trials Information","http:\u002F\u002Fwww.merckclinicaltrials.com",{"nct_id":4,"conditions":146,"biomarkers":147},[19],[],{"nct_id":4,"found":105,"summary":149,"prompt_version":159},{"design":150,"status":151,"heading":152,"summary":153,"follow_up":154,"word_count":155,"commitments":156,"compensation":157,"drugs_mentioned":158},"This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 30 healthy participants.","completed","A Study of MK-7262 and Enlicitide in Healthy Participants","This study is looking for healthy volunteers aged 19 to 55 to understand how two drugs, MK-7262 and Enlicitide, behave in the body. Specifically, researchers want to see how much of each drug is absorbed and how long it stays in your system after you take a single dose of both. To join, you should be in good general health with a body mass index (BMI) between 18 and 32. People with significant medical or mental health conditions cannot participate. The study aims to enroll 30 participants. The study's success will be measured by tracking the levels of MK-7262 and Enlicitide in your blood over about 8 days.","Your drug levels will be measured for up to 8 days after taking the doses.",108,"You will receive single doses of MK-7262 and Enlicitide. Blood samples will be taken before and at various times for up to 8 days after you take the drugs.","Not stated in the trial record.",[31,36],"v2"]